Roman Butler Fullerton & Co. Has $491,000 Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Roman Butler Fullerton & Co. raised its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 72.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 16,031 shares of the biotechnology company’s stock after buying an additional 6,757 shares during the period. Roman Butler Fullerton & Co.’s holdings in Corcept Therapeutics were worth $491,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in Corcept Therapeutics by 90.6% during the 1st quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock worth $31,000 after buying an additional 579 shares during the period. Park Place Capital Corp acquired a new stake in shares of Corcept Therapeutics during the second quarter worth about $32,000. Atwood & Palmer Inc. bought a new position in shares of Corcept Therapeutics during the 2nd quarter valued at about $35,000. Gladius Capital Management LP acquired a new position in shares of Corcept Therapeutics in the 4th quarter valued at approximately $36,000. Finally, FinTrust Capital Advisors LLC increased its stake in Corcept Therapeutics by 318.7% during the 1st quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,348 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Price Performance

NASDAQ:CORT traded up $0.03 on Tuesday, hitting $34.14. 524,386 shares of the company’s stock were exchanged, compared to its average volume of 1,301,647. The company has a market cap of $3.55 billion, a P/E ratio of 32.18 and a beta of 0.44. The firm has a 50-day moving average price of $32.65 and a 200-day moving average price of $27.42. Corcept Therapeutics Incorporated has a 52 week low of $20.84 and a 52 week high of $39.75.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Monday, July 29th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.09. The business had revenue of $163.80 million for the quarter, compared to analyst estimates of $155.14 million. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. Corcept Therapeutics’s revenue was up 39.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.25 earnings per share. On average, research analysts expect that Corcept Therapeutics Incorporated will post 1.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CORT has been the topic of a number of research reports. Piper Sandler lifted their price target on shares of Corcept Therapeutics from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $38.00 target price on shares of Corcept Therapeutics in a research note on Tuesday, July 30th. StockNews.com downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 3rd. Truist Financial reaffirmed a “buy” rating and set a $65.00 price objective on shares of Corcept Therapeutics in a research report on Monday, June 17th. Finally, HC Wainwright lifted their target price on Corcept Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Corcept Therapeutics has a consensus rating of “Buy” and an average target price of $46.50.

Insider Buying and Selling at Corcept Therapeutics

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $30.21, for a total value of $66,462.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $30.21, for a total transaction of $66,462.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider William Guyer sold 10,000 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $38.67, for a total value of $386,700.00. Following the completion of the sale, the insider now owns 6,039 shares in the company, valued at approximately $233,528.13. The disclosure for this sale can be found here. Insiders sold a total of 35,550 shares of company stock worth $1,178,759 over the last quarter. 20.50% of the stock is currently owned by insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.